Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) is the leading cause of death among women affected by gynaecological malignancies. Most patients show advanced disease at diagnosis (FIGO stage III-IV) and, despite the introduction of new therapeutic options, most women experience relapses. In most cases, recurrence...
Main Authors: | Giulia Scotto, Fulvio Borella, Margherita Turinetto, Valentina Tuninetti, Anna A. Valsecchi, Gaia Giannone, Stefano Cosma, Chiara Benedetto, Giorgio Valabrega |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/12/3408 |
Similar Items
-
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
by: Margherita Turinetto, et al.
Published: (2021-06-01) -
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
by: Fulvio Borella, et al.
Published: (2020-03-01) -
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers
by: Gloria Mittica, et al.
Published: (2020-05-01) -
From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia
by: Fulvio Borella, et al.
Published: (2022-04-01) -
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
by: Eleonora Ghisoni, et al.
Published: (2019-02-01)